Esperion Therapeutics (ESPR) Operating Margin (2019 - 2026)

Esperion Therapeutics has reported Operating Margin for 8 years, with the latest figure at 8.22% in Q1 2026.

• For the quarter ending Q1 2026, Operating Margin rose 2578.0% year-over-year to 8.22%; the trailing twelve-month figure through Mar 2026 stood at 18.12% (up 3352.0% YoY), and the FY2025 full-year result was 14.95%, down 142.0% from the prior year.
• Operating Margin for Q1 2026 stood at 8.22%, down from 50.6% in the prior quarter.
• The five-year high for Operating Margin was 52.47% in Q1 2024, with the low at 277.99% in Q2 2022.
• Historically, Operating Margin has averaged 87.25% across 5 years, with a median of 34.0% in 2025.
• The largest YoY upside for Operating Margin was 80993 bps in 2022 against a maximum downside of 19798 bps in 2022.
• Esperion Therapeutics' Operating Margin stood at 225.92% in 2022, then jumped by 42 bps to 131.37% in 2023, then jumped by 95 bps to 6.4% in 2024, then surged by 891 bps to 50.6% in 2025, then tumbled by 116 bps to 8.22% in 2026.
• The last three Operating Margin figures came in at 8.22% (Q1 2026), 50.6% (Q4 2025), and 11.41% (Q3 2025), per Business Quant data.